2024
Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront cost
2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosis
2022
Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model
Gao S, Jin L, Meadows H, Shafman T, Gross C, Yu J, Aerts H, Miccio J, Stahl J, Mak R, Decker R, Kann B. Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC: Development and External Validation of a Multi-Institutional Model. Journal Of Thoracic Oncology 2022, 18: 339-349. PMID: 36396062, DOI: 10.1016/j.jtho.2022.11.007.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyEarly-stage NSCLCBody radiation therapyDistant metastasisStage NSCLCRadiation therapyHigh-risk patient subgroupsExternal validationPatient-level riskMulti-institutional databaseTime-dependent areaGray regression modelsRandom survival forest modelDM riskSystemic therapyPatient subgroupsIndividualized riskNSCLCPatientsDM ratesDiscriminatory performanceRandom survival forestTherapyInternal validationGood calibration
2021
Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer
Abujarad F, Wang S, Ulrich D, Mougalian S, Killelea B, Fraenkel L, Gross C, Evans S. Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer. Lecture Notes In Computer Science 2021, 12780: 389-402. DOI: 10.1007/978-3-030-78224-5_27.Peer-Reviewed Original ResearchEarly-stage breast cancerOlder womenBreast cancerRadiation therapyTreatment therapiesEvidence-based treatment decisionsShared-decision modelRisk-benefit informationRisk calculatorRelative riskTreatment decisionsPatient healthDigital health toolsPatient comprehensionTherapyHealth toolsWomenCancerHealthPatientsClinicians
2020
Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.Peer-Reviewed Original ResearchThe association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.Peer-Reviewed Original ResearchBiomarker-driven therapiesBiomarker testingEvidence of testingYear of diagnosisQuality cancer careUS cancer patientsLikelihood of testingDe-identified databaseEvidence of receiptEligible ptsOverall survivalAdjusted analysisContemporary cohortMedicaid insuranceRetrospective studyCancer careCancer patientsWorse outcomesCancer clinicHigh riskCommercial insurancePrivate insuranceAdvanced diagnosisTherapyDiagnosisUtilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy
2019
An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.Peer-Reviewed Original Research
2018
Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers
Johnson S, Park H, Gross C, Yu J. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e399-e400. DOI: 10.1016/j.ijrobp.2018.07.1180.Peer-Reviewed Original ResearchSystemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis
Kann B, Miccio J, Stahl J, Verma V, Dosoretz A, Park H, Shafman T, Gross C, Yu J, Decker R. Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s10-s11. DOI: 10.1016/j.ijrobp.2018.06.119.Peer-Reviewed Original ResearchTreatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes.
Pariser A, Mougalian S, Sedghi T, Gross C, Killelea B. Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes. Journal Of Clinical Oncology 2018, 36: e12630-e12630. DOI: 10.1200/jco.2018.36.15_suppl.e12630.Peer-Reviewed Original Research
2016
Modern Radiation Therapy for Left-Sided Breast Cancer: An Analysis of Mean Heart Dose Within Diverse Practice Settings
Hong J, Gross C, Shafman T, Hu X, Yu J, Ross R, Dosoretz A, Park H, Finkelstein S, Soulos P, Evans S. Modern Radiation Therapy for Left-Sided Breast Cancer: An Analysis of Mean Heart Dose Within Diverse Practice Settings. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s209. DOI: 10.1016/j.ijrobp.2016.06.520.Peer-Reviewed Original ResearchA Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original ResearchOnset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.
Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.Peer-Reviewed Original Research
2015
Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer
Park H, Wang E, Corso C, Rutter C, Wilson L, Kim A, Gross C, Yu J, Decker R. Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186-s187. DOI: 10.1016/j.ijrobp.2015.07.447.Peer-Reviewed Original ResearchMP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMA
Han Y, Wietsma A, Gross C, Shah N, Abouassaly R, Smaldone M, Boorjian S, Hoimes C, Cooney M, Kim S. MP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMA. Journal Of Urology 2015, 193: e869-e870. DOI: 10.1016/j.juro.2015.02.2512.Peer-Reviewed Original Research
2014
Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population
Erb C, Soulos P, Tanoue L, Gross C. Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population. CHEST Journal 2014, 146: 607a. DOI: 10.1378/chest.1992085.Peer-Reviewed Original ResearchMP6-06 POPULATION-LEVEL TRENDS IN THE ADOPTION OF NOVEL TARGETED AGENTS FOR SYSTEMIC THERAPY AND IMPACT ON RATES OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA
Psutka S, Kim S, Gross C, Van Houten H, Thompson R, Abouassaly R, Weight C, Leibovich B, Shah N. MP6-06 POPULATION-LEVEL TRENDS IN THE ADOPTION OF NOVEL TARGETED AGENTS FOR SYSTEMIC THERAPY AND IMPACT ON RATES OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA. Journal Of Urology 2014, 191: e58. DOI: 10.1016/j.juro.2014.02.240.Peer-Reviewed Original Research
2013
The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit
Raldow A, Presley C, Yu J, Cramer L, Soulos P, Long J, Makarov D, Gross C. The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s177-s178. DOI: 10.1016/j.ijrobp.2013.06.459.Peer-Reviewed Original Research